Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Reiberger

Showing results (371-380 of 491) with videos related to

Pageof 50
Sort By:
Cell Death Discovery|August 2, 2023
Gas6 in chronic liver disease-a novel blood-based biomarker for liver fibrosisKatharina Staufer, Heidemarie Huber, Jasmin Zessner-Spitzenberg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 9, 2026
Prognostication of Liver Disease Patients via the WFUMB 'Rule-of-4' Algorithm Using SSI-2D-SWE-Based Liver Stiffness MeasurementChristian Sebesta, Georg Kramer, Nina Dominik, et al.
Journal of Hepatology|May 7, 2022
Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLDNina Bastati, Lucian Beer, Ahmed Ba-Ssalamah, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2020
Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal HypertensionKatharina Wöran, Georg Semmler, Mathias Jachs, et al.
Journal of Hepatology|September 6, 2025
Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80]Jose Ignacio Fortea, Edilmar Alvarado-Tapias, Benedikt Simbrunner, et al.
Hepatology (Baltimore, Md.)|December 23, 2014
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceYunching Chen, Rakesh R Ramjiawan, Thomas Reiberger, et al.
JHEP Reports : Innovation in Hepatology|December 3, 2024
Metabolomic profiles differentiate between porto-sinusoidal vascular disorder, cirrhosis, and healthy individualsGeorg Semmler, Oleksandr Petrenko, Juanjo Jose Lozano, et al.
Wiener Klinische Wochenschrift|April 13, 2013
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)Markus Peck-Radosavljevic, Bernhard Angermayr, Christian Datz, et al.
Scientific Reports|July 27, 2025
Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis modelsThomas Sorz-Nechay, Ksenia Brusilovskaya, Philipp Königshofer, et al.
Journal of Hepatology|December 19, 2024
Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosisJose Ignacio Fortea, Edilmar Alvarado-Tapias, Benedikt Simbrunner, et al.
Pageof 50

Showing results (371-380 of 491) with videos related to

Sort By:
Pageof 50
Cell Death Discovery|August 2, 2023
Gas6 in chronic liver disease-a novel blood-based biomarker for liver fibrosisKatharina Staufer, Heidemarie Huber, Jasmin Zessner-Spitzenberg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 9, 2026
Prognostication of Liver Disease Patients via the WFUMB 'Rule-of-4' Algorithm Using SSI-2D-SWE-Based Liver Stiffness MeasurementChristian Sebesta, Georg Kramer, Nina Dominik, et al.
Journal of Hepatology|May 7, 2022
Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLDNina Bastati, Lucian Beer, Ahmed Ba-Ssalamah, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2020
Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal HypertensionKatharina Wöran, Georg Semmler, Mathias Jachs, et al.
Journal of Hepatology|September 6, 2025
Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80]Jose Ignacio Fortea, Edilmar Alvarado-Tapias, Benedikt Simbrunner, et al.
Hepatology (Baltimore, Md.)|December 23, 2014
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceYunching Chen, Rakesh R Ramjiawan, Thomas Reiberger, et al.
JHEP Reports : Innovation in Hepatology|December 3, 2024
Metabolomic profiles differentiate between porto-sinusoidal vascular disorder, cirrhosis, and healthy individualsGeorg Semmler, Oleksandr Petrenko, Juanjo Jose Lozano, et al.
Wiener Klinische Wochenschrift|April 13, 2013
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)Markus Peck-Radosavljevic, Bernhard Angermayr, Christian Datz, et al.
Scientific Reports|July 27, 2025
Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis modelsThomas Sorz-Nechay, Ksenia Brusilovskaya, Philipp Königshofer, et al.
Journal of Hepatology|December 19, 2024
Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosisJose Ignacio Fortea, Edilmar Alvarado-Tapias, Benedikt Simbrunner, et al.
Pageof 50